CAC
APLS

Cowen and Company’s Apellis Pharmaceuticals APLS Stock Holding History

Cowen and Company’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-66,470
Closed -$3.98M – 673
2023
Q4 		$3.98M Buy
+66,470
New +$3.37M 0.26% 65
2023
Q1 		– Sell
-5,000
Closed -$259K – 571
2022
Q4 		$259K Sell
5,000
-14,000
-74% -$743K 0.03% 160
2022
Q3 		$501K Buy
19,000
+16,008
+535% +$947K 0.05% 118
2022
Q2 		$135K Buy
2,992
+1,762
+143% +$80.3K 0.01% 225
2022
Q1 		$62K Buy
+1,230
New +$54.3K 0.01% 312
2021
Q4 		– Sell
-57,889
Closed -$1.91M – 641
2021
Q3 		$1.91M Buy
57,889
+50,133
+646% +$2.82M 0.09% 101
2021
Q2 		$490K Buy
+7,756
New +$400K 0.03% 183

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's APLS Position: Q1 2024 in Review

Cowen and Company sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 66,470 shares — an estimated $3.98M sold.

Cowen and Company first reported a position in APLS in Q2 2021 and held it in 7 quarters. The position peaked at $3.98M in Q4 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Cowen and Company reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 66,470 Apellis Pharmaceuticals shares in Q1 2024, an estimated $3.98M.
  • Cowen and Company first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Cowen and Company's Apellis Pharmaceuticals position peaked at $3.98M in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.